XML 39 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration Agreements (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2018
Jul. 31, 2017
Sep. 30, 2015
Mar. 31, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Revenue             $ 6,829,000        
Gain on termination of collaboration agreement     $ 4,398,000         $ 4,398,000      
Neurocrine Biosciences [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from upfront fee $ 50,000,000                    
Upfront payment received in cash 30,000,000                    
Upfront payment received in equity investment 20,000,000                    
Potential Milestone Payments Receivable 1,692,500,000           1,692,500,000        
Receivable from related party 448,000           448,000        
Deferred revenue $ 30,452,000           30,452,000        
Neurocrine Biosciences [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Revenue             2,881,000        
Neurocrine Biosciences [Member] | Research And Development Funding                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Revenue             $ 448,000        
Neurocrine Biosciences [Member] | Common Shares [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Maximum ownership limitation percentage for equity issuable 19.90%           19.90%        
Neurocrine Biosciences [Member] | Regulatory Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable $ 1,067,500,000           $ 1,067,500,000        
Neurocrine Biosciences [Member] | Sales Based Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable 600,000,000           600,000,000        
Neurocrine Biosciences [Member] | IND Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable $ 25,000,000           $ 25,000,000        
Percentage of milestone payment 55.00%           55.00%        
Percentage of premium on weighted average price             15.00%        
Neurocrine Biosciences [Member] | Neurocrine Collaboration Agreement [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront payment received in cash             $ 30,000,000        
Upfront payment received in equity investment             $ 20,000,000        
Percentage of option to co-fund development costs upon achievement of certain milestones             50.00%        
Collaborate agreement premium related to equity investment             $ 3,333,000        
Revenue             33,333,000        
Neurocrine Biosciences [Member] | Neurocrine Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Transaction price allocated to performance obligations $ 28,807,000           28,807,000        
Neurocrine Biosciences [Member] | Neurocrine Collaboration Agreement [Member] | Development Services Under the Initial Development Program For DTCs [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Transaction price allocated to performance obligations $ 4,526,000           4,526,000        
Flexion [Member] | Asset Purchase Agreement [Member] | XEN402 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from upfront fee   $ 3,000,000                  
Flexion [Member] | Asset Purchase Agreement [Member] | ASC 606 [Member] | XEN402 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from initiation of first GLP toxicology study   500,000                  
Flexion [Member] | Asset Purchase Agreement [Member] | Eligible to Receive CMC Development and Regulatory Milestone Payments [Member] | Maximum [Member] | XEN402 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable   9,000,000                  
Flexion [Member] | Asset Purchase Agreement [Member] | Future Clinical Development And Global Regulatory Approval Milestone Payments [Member] | Maximum [Member] | XEN402 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable   40,750,000                  
Flexion [Member] | Asset Purchase Agreement [Member] | Commercial Milestone Payments [Member] | Maximum [Member] | XEN402 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable   $ 75,000,000                  
Teva Canada Limited [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Number of common shares transferred and assigned for cancellation     1,000,000                
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Collaborative development and license agreement termination date     Mar. 31, 2018                
Genentech [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from upfront fee           $ 1,500,000          
Potential Milestone Payments Receivable           $ 1,500,000         $ 613,000,000
Milestone payment received       $ 250,000 $ 250,000            
Additional milestone payments or royalties received             $ 0        
Genentech [Member] | GDC-0276 [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from upfront fee                     10,000,000
Genentech [Member] | Regulatory Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable                     387,500,000
Genentech [Member] | Sales Based Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable                     180,000,000
Genentech [Member] | Development [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment received                   $ 5,000,000  
Genentech [Member] | Health Canada [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment received                 $ 8,000,000    
Genentech [Member] | Pre-clinical And Clinical Milestone [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Potential Milestone Payments Receivable                     45,500,000
Genentech [Member] | Licensing Agreements [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from upfront fee                     $ 10,000,000